|
Brussels, |
|
Read the Table of Content
|
eDossier EUPHARMA
PHARMACEUTICAL
|
Before purchasing an additional eEuropa product, please log in to your eEuropa account first, then return to this page to complete your purchase.
|
Summary
This eDossier offers a comprehensive analysis of the European Union's regulatory framework governing Pharmaceutical Products, alongside recent initiatives and legislative developments. It delves into the EU's efforts to ensure the safety, efficacy, and quality of medicinal products for human use while promoting innovation and competitiveness within the pharmaceutical industry.
The dossier covers key regulations, including the EU's Pharmaceutical Strategy for Europe, the revision of general pharmaceutical legislation, and specific directives related to the authorization, monitoring, and pharmacovigilance of medicinal products. It examines initiatives aimed at enhancing access to affordable medicines, addressing unmet medical needs, and fostering the development of advanced therapies and personalized medicine.
Additionally, the eDossier explores the impact of recent events, such as the COVID-19 pandemic, on EU pharmaceutical policies. It highlights measures taken to strengthen supply chains, improve crisis preparedness, and accelerate the development and approval of vaccines and treatments.
The document also addresses the EU's approach to digitalization in healthcare, including the use of health data and the integration of artificial intelligence in drug development and regulatory processes.
By providing in-depth information on current legislative work, regulatory procedures, and policy debates, this eDossier equips stakeholders with the knowledge needed to navigate the complex EU pharmaceutical landscape.
It enables professionals, policymakers, and industry to engage effectively with European institutions and contribute to shaping the future of pharmaceutical regulation in the EU.
The dossier covers key regulations, including the EU's Pharmaceutical Strategy for Europe, the revision of general pharmaceutical legislation, and specific directives related to the authorization, monitoring, and pharmacovigilance of medicinal products. It examines initiatives aimed at enhancing access to affordable medicines, addressing unmet medical needs, and fostering the development of advanced therapies and personalized medicine.
Additionally, the eDossier explores the impact of recent events, such as the COVID-19 pandemic, on EU pharmaceutical policies. It highlights measures taken to strengthen supply chains, improve crisis preparedness, and accelerate the development and approval of vaccines and treatments.
The document also addresses the EU's approach to digitalization in healthcare, including the use of health data and the integration of artificial intelligence in drug development and regulatory processes.
By providing in-depth information on current legislative work, regulatory procedures, and policy debates, this eDossier equips stakeholders with the knowledge needed to navigate the complex EU pharmaceutical landscape.
It enables professionals, policymakers, and industry to engage effectively with European institutions and contribute to shaping the future of pharmaceutical regulation in the EU.
* DaaS, Cloud-Based
This publication is offered as an eDossier DaaS, combining an updated digital document with 12-month cloud-based access. Subscribers can access both the web version and the PDF version online from computers, tablets or smartphones.
The document is not sold as a static file. It remains an updated eEuropa intelligence resource during the subscription period. Updates may include regulatory changes, new EU guidance, market developments and additional source links.
Access is provided for one year from subscription. Ownership of the document is not transferred; subscribers receive access rights to the updated eDossier according to the applicable licence terms.
This publication is offered as an eDossier DaaS, combining an updated digital document with 12-month cloud-based access. Subscribers can access both the web version and the PDF version online from computers, tablets or smartphones.
The document is not sold as a static file. It remains an updated eEuropa intelligence resource during the subscription period. Updates may include regulatory changes, new EU guidance, market developments and additional source links.
Access is provided for one year from subscription. Ownership of the document is not transferred; subscribers receive access rights to the updated eDossier according to the applicable licence terms.
